Infection-related hospitalizations are associated with increased mortality in patients with inflammatory bowel diseases

Journal of Crohn's and Colitis

Volumn 7, Issue 2, 2013, Pages 107-112

  Ananthakrishnan, Ashwin N ^a,b   McGinley, Emily L ^c  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

Crohn's disease; Immunosuppression; Infections; Ulcerative colitis

Indexed keywords

ADULT; AGED; ARTICLE; CLOSTRIDIUM DIFFICILE INFECTION; COMORBIDITY; CONTROLLED STUDY; CROHN DISEASE; DISEASE ASSOCIATION; FEMALE; HOSPITAL INFECTION; HOSPITALIZATION; HOSPITALIZATION COST; HUMAN; INTESTINE SURGERY; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MALNUTRITION; PNEUMONIA; PRIORITY JOURNAL; SEPSIS; TOTAL PARENTERAL NUTRITION; ULCERATIVE COLITIS; URINARY TRACT INFECTION;

ADULT; AGE FACTORS; AGED; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; COLITIS, ULCERATIVE; CONFIDENCE INTERVALS; CROHN DISEASE; FEMALE; HOSPITAL MORTALITY; HOSPITALIZATION; HUMANS; LENGTH OF STAY; MALE; MALNUTRITION; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; PARENTERAL NUTRITION, TOTAL; PNEUMONIA; RISK FACTORS; SEPSIS; YOUNG ADULT;

EID: 84872494665     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1016/j.crohns.2012.02.015     Document Type: Article

References (23)

1. Bewtra M., Su C., Lewis J.D. Rising hospitalization rates for Crohn's disease but not Ulcerative Colitis in the United States. Digestive Disease Week, Los Angeles, CA 2006.
2. Afif W., Loftus E.V. Safety profile of IBD therapeutics: infectious risks. Gastroenterol Clin North Am 2009, 38:691-709.
3. Bewtra M., Lewis J.D. Safety profile of IBD: lymphoma risks. Gastroenterol Clin North Am 2009, 38:669-689.
4. Bossuyt P., Verhaegen J., Van Assche G., Rutgeerts P., Vermeire S. Increasing incidence of Clostridium difficile-assiociated diarrhea in inflammatory bowel disease. J Crohns Colitis 2009, 3:4-7.
5. Hanauer S.B., Feagan B.G., Lichtenstein G.R., Mayer L.F., Schreiber S., Colombel J.F., et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002, 359:1541-1549.
6. Ananthakrishnan A.N., McGinley E.L., Binion D.G. Excess hospitalisation burden associated with Clostridium difficile in patients with inflammatory bowel disease. Gut 2008, 57:205-210.
7. Nguyen G.C., Leung W., Weizman A.V. Increased risk of vancomycin-resistant enterococcus (VRE) infection among patients hospitalized for inflammatory bowel disease in the United States. Inflamm Bowel Dis 2011 Jun, 17(6):1338-1342.
8. Nguyen G.C., Patel H., Chong R.Y. Increased prevalence of and associated mortality with methicillin-resistant Staphylococcus aureus among hospitalized IBD patients. Am J Gastroenterol 2010, 105:371-377.
9. Toruner M., Loftus E.V., Harmsen W.S., Zinsmeister A.R., Orenstein R., Sandborn W.J., et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology 2008, 134:929-936.
10. Fidder H., Schnitzler F., Ferrante M., Noman M., Katsanos K., Segaert S., et al. Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study. Gut 2009, 58:501-508.
11. Steiner C., Elixhauser A., Schnaier J. The healthcare cost and utilization project: an overview. Eff Clin Pract 2002, 5:143-151.
12. Ananthakrishnan A.N., McGinley E.L., Saeian K., Binion D.G. Temporal trends in disease outcomes related to Clostridium difficile infection in patients with inflammatory bowel disease. Inflamm Bowel Dis 2011, 17:976-983.
13. Nguyen G.C., Kaplan G.G., Harris M.L., Brant S.R. A national survey of the prevalence and impact of Clostridium difficile infection among hospitalized inflammatory bowel disease patients. Am J Gastroenterol 2008, 103:1443-1450.
14. Kaplan G.G., McCarthy E.P., Ayanian J.Z., Korzenik J., Hodin R., Sands B.E. Impact of hospital volume on postoperative morbidity and mortality following a colectomy for ulcerative colitis. Gastroenterology 2008, 134:680-687.
15. Elixhauser A., Steiner C., Harris D.R., Coffey R.M. Comorbidity measures for use with administrative data. Med Care 1998, 36:8-27.
16. Jen M.H., Saxena S., Bottle A., Aylin P., Pollok R.C. Increased health burden associated with Clostridium difficile diarrhoea in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2011, 33:1322-1331.
17. Ananthakrishnan A.N., McGinley E.L., Binion D.G. Inflammatory bowel disease in the elderly is associated with worse outcomes: a national study of hospitalizations. Inflamm Bowel Dis 2009, 15:182-189.
18. O'Grady N.P., Alexander M., Dellinger E.P., Gerberding J.L., Heard S.O., Maki D.G., et al. Guidelines for the prevention of intravascular catheter-related infections. Infect Control Hosp Epidemiol 2002, 23:759-769.
19. Mahadevan U., Cucchiara S., Hyams J.S., Steinwurz F., Nuti F., Travis S.P., Sandborn W.J., Colombel J.F. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organisation: pregnancy and pediatrics. Am J Gastroenterol 2011, 106:214-223. quiz 224.
20. Siegel C.A., Melmed G.Y. Predicting response to Anti-TNF Agents for the treatment of Crohn's disease. Ther Adv Gastroenterol 2009, 2:245-251.
21. Rahier J.F., Ben-Horin S., Chowers Y., Conlon C., De Munter P., D'Haens G., et al. European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis 2009, 3:47-91.
22. Issa M., Ananthakrishnan A.N., Binion D.G. Clostridium difficile and inflammatory bowel disease. Inflamm Bowel Dis 2008, 14:1432-1442.
23. Gould C.V., Umscheid C.A., Agarwal R.K., Kuntz G., Pegues D.A. Guideline for prevention of catheter-associated urinary tract infections. Infect Control Hosp Epidemiol 2009, 31:319-326.